ARTICLE | Management Tracks
Heaton to join Janssen as global head for vaccines; plus AstraZeneca promotes Galbraith, Ribometrix, Shoreline, Ribon and more
June 29, 2021 1:36 AM UTC
Penny Heaton said via a social media post that she will be stepping down as the CEO from Bill & Melinda Gates Medical Research Institute, to join the Janssen Pharmaceutical unit of Johnson & Johnson (NYSE:JNJ) in September as global therapeutics area head for vaccines. Johan Van Hoof, current global therapeutics area head of vaccines and managing director at Janssen Vaccines and Prevention B.V., will retire in 2022.
Susan Galbraith became EVP of oncology R&D at AstraZeneca plc (LSE:AZN; NASDAQ:AZN), succeeding Jose Baselga, who passed away in March. Galbraith joined the company in 2010 as SVP of innovative medicines and early development oncology, and recently served as SVP of early oncology...